use in the community (spillover effect). CONCLUSIONS: Evergreening drugs successfully compete with generics, offsetting cost containment strategies including generic medication substitution or a hospital RDF, particularly so if hospitals include evergreening or brand drugs on their RDF. For effectiveness, prescriptions should be coordinated at the state level rather than from a payer perspective, or hospitals should implement strategies to systematically switch patients to generic drugs at discharge.
OBJECTIVES:
To review the impact orphan drug (OD) legislation has had on innovation and pricing of therapeutic products for rare diseases in the US, EU, and Japan. METHODS: A systematic literature review was conducted, seeking Englishlanguage studies published after the enactment of initial OD legislation in 1983. EMBASE, Medline, and Business Source Complete were searched and results screened for studies specifically assessing the impact of industry-focused policy interventions using 1) measurable innovation-and pricing-related outcomes, and 2) specifying appropriate comparators. In addition to being abstracted for information on research setting, counterfactuals, outcomes, and findings, the methodological quality of included studies was evaluated with an adapted tool. RESULTS: Twenty unique studies met the inclusion criteria: 14 discussing innovation outcomes and 7 discussing pricing outcomes. Increasingly strong study designs have been used to validate that that OD legislation has increased cross-market approv-als and suggest the increasing role of small biotechnology companies. Select research also shows a positive relationship between disease prevalence and the likelihood of indicated ODs and is bolstered by well-controlled regression-continuity studies showing sustained innovation in higher prevalence OD markets. However, some concerns are raised regarding innovation in low prevalence conditions and conditions just above OD thresholds. Pricing studies were almost exclusively focused on the EU. A multiple-regression analysis demonstrated that merely having an OD designation leads to a higher price, with 4 weaker studies suggesting an inverse relationship between rare disease prevalence and acquisition price. CONCLUSIONS: Despite an abundance of opinion and case study pieces in OD literature, specific studies of high internal validity exist, as do defined and usable comparator group classifications. The reviewed studies ought to serve as valuable information for policymakers considering policy extensions for ultra-orphans, international markets, or other niche therapeutic areas, as well as demonstration of best-practices in designing well-controlled studies evaluating biopharmaceutical policies. The Japanese generic drug market is not well developed. The generic volume share is 20% of the total market vs. 74% and 64% in the USA and UK. The slow uptake of generics is often explained by the "Brand Lover" profile of Japan. No formal review of drug policy has been undertaken to understand the slow uptake of generics. OBJECTIVES: To review the current Japanese drug policy regarding generic drugs and to appreciate the incentive and disincentive to use generic. METHODS: We reviewed the current Japanese generic drug policy enacted by the Ministry of Health, Labour and Welfare (MHLW), and the Japanese Generic Medicines Association's website. RESULTS: Major policies to enhance generic uptake were issued in 2002, 2006 and 2010. They required that prescriptions specify if substitution generics are acceptable, and provide some modest financial incentives for pharmacies and hospitals to substitute only with the patient's agreement. In 2012, INN prescription is encouraged but not requested. The recent introduction of Japanese DRG hospital funding, and the 2011 Japan-India Economic Partnership Agreement, which opened the Japanese market to Indian generic drug manufacturers, are expected to boost the generic market. However, small pricing gaps between generic and branded drugs, the lack of mandatory substitution and INN prescription, little price discounting and little education towards the public might explain the slow uptake of generics in Japan, relative to the West. CONCLUSIONS: Although the "Brand Lover" assumption is candidly used to explain the lack of traction by generic drugs, this review finds the lack of policy incentives to boost generic adoption, better explain current levels of generics penetration. Shall the authorities be willing to encourage generic uptake more effective policy incentive are needed.
PHP16 GENERIC DRUG MARKET ACCESS IN JAPAN

PHP17
ROLE OF SUBGROUP ANALYSES FOR TECHNOLOGY ASSESSMENT AND COVERAGE DECISIONS
Aggarwal S Novel Health Strategies, Bethesda, MD, USA OBJECTIVES: Cost effectiveness analyses play a critical role in determining coverage of novel drugs and devices. Increasingly, payers are demanding subgroup analyses to determine indications which would be covered by the national health system or insurance agency. METHODS: To understand and review trends in use of subgroup cost effectiveness analysis, we analyzed NICE HTAs for products approved in 2011-2012. Manufacturer submissions for CEA were compared to final review and decision by HTA agency. Analogs were identified and case studies were developed to further understand the use of subgroup analyses and cost effectiveness models. RESULTS: Decisions made by NICE in 2011-2012 show increasing trends towards the use of subgroup analysis for determining indications for coverage by national payer bodies. During 2011-2012, 80% of the assessments included subgroup analyses. Approximately half of them included cost effectiveness analyses for various subgroups. Interestingly, the ICER values estimated by NICE for the same subgroups showed a large variation (1X-3X fold difference) compared to ICER values estimated by manufacturers. Selected case studies highlighted that for several products NICE is recommending treatments only for subgroups whose ICER values are within the cost effectiveness threshold. CONCLUSIONS: New products need robust broader population and subgroup analyses for insurance coverage.
PHP18 THE EFFECT OF LAW FOR ECONOMICAL USE OF MEDICATIONS 2006 ON THE CATCHMENT POPULATION OF COMMUNITY PHARMACIES BETWEEN 2007-2010
Boncz I 1 , Donka-Verebes É 2 , Oberfrank F 3 1 University of Pécs, Pécs, Hungary, 2 Integra Consulting zRt., Budapest, Hungary, 3 Institute of Experimental Medicine (IEM)., Budapest, Hungary OBJECTIVES: In 2006 a law for the economical use of medications was introduced into the Hungarian legislation. This law -among others -facilitated the foundation of new pharmacies. The aim of our study is to analyse the effect of that legislation on the catchment population of community pharmacies. METHODS: Data were derived from the pharmaceutical database of the Hungarian Health Insurance Fund Administration (OEP), the only health care financing agency in Hungary. We analysed the 5 years period between 2006-2010. The main indicator of our analyses is the average population of one pharmacy (catchment population) in the counties of Hungary. RESULTS: The average catchment population of a pharmacy was 4933 inhabitants ((Ϯ 592, standard deviation, SD) in 2006, while in 2010 it decreased to 3.888 (Ϯ 450) inhabitants per pharmacy. We found the largest catchment popula-A291 tion in 2006 in the following counties: Vas (6.326 inhabitants/pharmacy), Pest (5.913 inhabitants/pharmacy) and Nógrád (5.855 inhabitants/pharmacy), while the smallest: Bács-Kiskun (4.034 inhabitants/pharmacy), Békés (4.165 inhabitants/pharmacy) and Somogy (4.218 inhabitants/pharmacy). In 2010 Nógrád (5.123 inhabitants/pharmacy), Vas (4.632 inhabitants/pharmacy) and Pest (4.424 inhabitants/ pharmacy) counties had the largest catchment population, while Bács-Kiskun (3.222 inhabitants/pharmacy), Békés (3.458 inhabitants/pharmacy) and Csongrád (3.441 inhabitants/pharmacy) had the lowest. CONCLUSIONS: Between 2007-2010, as the consequence of the increasing number of pharmacies, the average catchment population of pharmacies decreased significantly. The regional differences among counties did not change during the study period and remained high.
OBJECTIVES:
As treatments trend towards personalized medicine for conditions with certain genetic expressions, new opportunities exist for diagnostic tests to change the standard of care and demonstrate positive economic impact to payers. A systematic review of the role of economic evaluation to the coverage and payment of novel diagnostics has not yet been performed. The authors undertook this analysis to examine what evidence exists to document the use of health economic rationale and modeling to impact reimbursement and market access outcomes for diagnostics. METHODS: A systematic review of published literature related to the reimbursement and health technology assessment of diagnostics was conducted. In addition, published coverage policies and HTAs in the US, UK, and Germany related to personalized medicine diagnostics commercialized within the last decade were reviewed. Policies and HTAs were graded to document the level of impact economics played to decision-outcomes, if reported. Where specific references were not made, a review of the citations referenced was conducted to see if economic papers or models were included within their decision-framework. RESULTS: Most published personalized medicine diagnostic coverage policies and HTAs reference both clinical and economic evidence, though clinical data is prioritized. Of the policies analyzed, national HTA groups that reviewed novel diagnostics or products with companion diagnostics, were most explicit in their consideration of clinical and economic data. US payers were less likely to explicitly reference economic data. CONCLUSIONS: As treatments are becoming more and more dependent on companion diagnostic tests to influence treatment of disease in a variety of subgroups, the processes by which diagnostics are approved, covered, and reimbursed will become more scrutinized. More standardized and transparent incorporation of economic rationale and modeling into payer coverage, payment, and HTA evaluation processes would clarify expectations and help companies plan for HEOR activities.
PHP21 HOW WILL THE NEW NHS DECENTRALISED REFORMS IMPACT ON ACCESS TO MEDICINES IN ENGLAND?
Assimakopoulos M, White R Access Partnership, London, UK OBJECTIVES: With the formation of Clinical Commissioning Groups (CCGs) GP Practices will come together to commission services for their local populations. However, freedoms to be delegated from the Clinical Commissioning board may mean that considerable 'command and control' will still be exerted from the centre. Secondary and primary research was undertaken to gain insight into how devolved locality based commissioning is likely to impact on access to medicines. METHODS: We reviewed 35 first wave CCGs in terms of population coverage, financial stability and current Primary care Trust (PCT) activities in relation to Practice based commissioning. We then interviewed 5 NHS Experts to assess whether these CCGs would be allowed the aspirational freedoms referred to in the 2012 Health and Social Care Act-in particular prescribing freedoms formerly under the guidance of PCTs. Various information sources were used Care Quality Commission, Audit Commission, and Health Select Committee reports to support the interpretation of the findings. RESULTS: The selected CCGs represented an homogeneous group of practices in that they had previously demonstrated financial stewardship and collaborative working with their 'host' PCTs. Many CCGs had been devolved the Commissioning budget by their PCTs and were routinely involved in setting up medicines management protocols with their provider hospitals. Almost half of the CCGs had coterminous medicines management contracts shared with their PCTs. NHS experts raised issues around corporate and clinical governance and how practices would fundamentally want to take on the devolved financial responsibilities. CONCLUSIONS: The NHS reforms mean that £60 Billion of the total health care budget will be under the control of CCGs. PCTs and Strategic Health Authorities will be abolished and with a watered down role for NICE postcode variation may be rife; access to medicines will continue to be fraught with many layers of decision making and further delays.
PHP22 PHARMACOVIGILANCE IN QATAR -A PHARMACIST SURVEY
Wilbur K Qatar University, Doha, Qatar OBJECTIVES: Active domestic pharmacovigilance programs are necessary as adverse drug reaction (ADR) data from other countries may overlook safety patterns in local populations. The success of any surveillance system relies upon active participation of reporters. The objective of this study was to describe pharmacist reporting of suspected ADRs in Qatar to inform policy recommendations to the Supreme Council of Health. METHODS: A 27-item survey was developed following comprehensive literature review of relevant published research. Questions encompassed broad domains including: pharmacist knowledge of and experiences in reporting suspected ADRs; attitudes towards health professional pharmacovigilance roles; perceived barriers and facilitators to reporting; and recommendations for improvements in this process. The web-based survey was formatted for electronic delivery and response for self-administration in English or Arabic by a convenience sample of over 500 Qatar pharmacists. RESULTS: The survey remained open for two months between April 30 and June 30, 2011. Of the 142 (25%) total responses, 116 (81.6%) surveys were completed beyond demographic data and included information about prior suspected ADR reporting experiences. Knowledge of ADR terminology and reporting purpose among the 116 (20%) responding pharmacists was high, but only 34 (30%) had ever made a suspected ADR report in Qatar. Most respondents expressed positive attitudes towards pharmacist roles in pharmacovigilance activities, but inability to recognize a potential ADR or subsequently access a reporting form were perceived barriers, with enhanced training and efficiency in report submission corresponding identified facilitators to future participation. Hospital pharmacists were 7 times more likely than ambulatory-care based pharmacists to have reported a suspected ADR in Qatar. CONCLUSIONS: Pharmacists in Qatar are willing to engage in pharmacovigilance activities if supported by increased training and transparency in the reporting process. A national infrastructure with capacity to collect and manage suspected ADR reports and promote patient and medication safety is exigent.
PHP23 THE EARLY BENEFIT ASSESSMENT OF NEW PHARMACEUTICALS IN GERMANY ("AMNOG"): A STRUCTURED SURVEY ANALYSIS ONE YEAR AFTER ENACTMENT
Stoeckel F 1 , Neubauer AS 2 1 University of Bayreuth, Bayreuth, Germany, 2 IfG Institute for Health Economics, München, Germany OBJECTIVES: In January 2011, the act for restructuring the pharmaceutical market ("AMNOG") was introduced in Germany. We analyzed the effects one year after AMNOG's implementation in an empirical study. The research focused on surveying affected stakeholders, systematically summarizing their experiences, and identifying topics of controversy. METHODS: Stakeholders were defined based on statements during the AMNOG legislation: Payors, Pharmaceutical Industry, National Regulatory Bodies, Scientific Experts, Patients, Care Providers, Politicians, Pharmacies and External Service Providers. The benefit assessement process was structured into 6 topics: Market Launch, Early Benefit Assessment, Price Negotiations, Arbitration Procedure, Cost-Benefit Analysis and Process. 45 experts participated in the structured survey (26% response rate), which consisted of closed questions supplemented by optional open-ended questions (total 47 items). Descriptive statistical and dissimilarity analyses were performed. RESULTS: Between the 9 stakeholder groups, several items were highly controversial: negotiation position of statutory health insurances ("GKV-Spitzenverband") in rebate level negotiations (distance index L 2 ϭ1.17), use of European price reference in the arbitration process (L 2 ϭ1.08) and several others such as transparency of the benefit assessment process (L 2 ϭ0.95). Different response profiles were observed between stakeholders but they yielded relatively low dissimilarities on cost-benefit assessment.
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